A Novel Endoplasmic Reticulum Stress-related LncRNA Prognostic Risk Model for Cutaneous Melanoma

Overview

Journal J Cancer Res Clin Oncol

Specialty Oncology

Date 2022 Jun 10

PMID 35687183

Authors

An-An Li

Fan Li

Min Lan

Yu Zhang

Dong Xie

Mei-Ying Yan

Affiliations

Soon will be listed here.

Abstract

Objective: Endoplasmic reticulum stress (ERS) and long non-coding RNAs (lncRNAs) are important in melanoma development and progression. This study aimed to explore the prognostic value of ERS-associated lncRNA profiles in cutaneous melanoma (CM).

Methods: The Cancer Genome Atlas (TCGA) provides the raw data of CM. GSEA website was used to obtain ERS-related genes, and mRNA and LncRNA co-expression network were used to obtain ERS-related lncRNAs. A Lasso regression analysis was used to identify a prognostic risk model for the composition of ERS-related lncRNAs. Patients were divided into high- and low-risk groups based on the model's risk score. The researchers then compared the two groups' survival rates, immune infiltration, chemotherapeutic drug sensitivity, and immune checkpoint gene expression.

Results: Thirty-nine ERS-related lncRNAs were discovered to be prognostic. A prognostic risk model made up of ten ERS-related lncRNAs was discovered. Patients in the low-risk group had a better prognosis than those in the high-risk group. An examination of tumor microenvironment revealed that risk scores correlated with immune cell infiltration in eight cases. Dacarbazine, paclitaxel, and cisplatin, three chemotherapy drugs, were more sensitive in the low-risk group than in the high-risk group.

Conclusion: This study identified a risk model of ten ERS-related lncRNAs that have significant prognostic value in CM and could help guide clinical treatment.

Citing Articles

Construction of an endoplasmic reticulum stress and cuproptosis -related lncRNAs signature in chemosensitivity in hepatocellular carcinoma by comprehensive bioinformatics analysis.

Qi X, Luo G, Tuersun A, Chen M, Wu G, Zheng L Heliyon. 2024; 10(19):e38342.

PMID: 39398070 PMC: 11471205. DOI: 10.1016/j.heliyon.2024.e38342.

References

Arslanbaeva L, Santoro M . Adaptive redox homeostasis in cutaneous melanoma. Redox Biol. 2020; 37:101753. PMC: 7578258. DOI: 10.1016/j.redox.2020.101753. View

Atkins M, Curiel-Lewandrowski C, Fisher D, Swetter S, Tsao H, Aguirre-Ghiso J . The State of Melanoma: Emergent Challenges and Opportunities. Clin Cancer Res. 2021; 27(10):2678-2697. PMC: 8127340. DOI: 10.1158/1078-0432.CCR-20-4092. View

Bomar L, Senithilnathan A, Ahn C . Systemic Therapies for Advanced Melanoma. Dermatol Clin. 2019; 37(4):409-423. DOI: 10.1016/j.det.2019.05.001. View

Bray F, Ferlay J, Soerjomataram I, Siegel R, Torre L, Jemal A . Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018; 68(6):394-424. DOI: 10.3322/caac.21492. View

Bremnes R, Busund L, Kilvaer T, Andersen S, Richardsen E, Paulsen E . The Role of Tumor-Infiltrating Lymphocytes in Development, Progression, and Prognosis of Non-Small Cell Lung Cancer. J Thorac Oncol. 2016; 11(6):789-800. DOI: 10.1016/j.jtho.2016.01.015. View

Dillon L, McPhee M, Davidson R, Quick A, Martin B, Covington K . Expanded evidence that the 31-gene expression profile test provides clinical utility for melanoma management in a multicenter study. Curr Med Res Opin. 2022; 38(8):1267-1274. DOI: 10.1080/03007995.2022.2033560. View

Dowling J, McGregor S, Williford P . Update on Current Treatment Recommendations for Primary Cutaneous Melanoma. Dermatol Clin. 2019; 37(4):397-407. DOI: 10.1016/j.det.2019.06.001. View

Eggermont A, Chiarion-Sileni V, Grob J, Dummer R, Wolchok J, Schmidt H . Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy. N Engl J Med. 2016; 375(19):1845-1855. PMC: 5648545. DOI: 10.1056/NEJMoa1611299. View

Fan Y, Liang X, Yu D . Low expression of endoplasmic reticulum stress-related gene SERP1 is associated with poor prognosis and immune infiltration in skin cutaneous melanoma. Aging (Albany NY). 2021; 13(19):23036-23071. PMC: 8544316. DOI: 10.18632/aging.203594. View

10.

Gambichler T, Tsagoudis K, Kiecker F, Reinhold U, Stockfleth E, Hamscho R . Prognostic significance of an 11-gene RNA assay in archival tissue of cutaneous melanoma stage I-III patients. Eur J Cancer. 2020; 143:11-18. DOI: 10.1016/j.ejca.2020.10.016. View

11.

Guo J, Yin S, Liu H, Liu F, Gao F . Tumor microenvironment immune-related lncRNA signature for patients with melanoma. Ann Transl Med. 2021; 9(10):857. PMC: 8184426. DOI: 10.21037/atm-21-1794. View

12.

Hersey P, Zhang X . Adaptation to ER stress as a driver of malignancy and resistance to therapy in human melanoma. Pigment Cell Melanoma Res. 2008; 21(3):358-67. DOI: 10.1111/j.1755-148X.2008.00467.x. View

13.

Hinshaw D, Shevde L . The Tumor Microenvironment Innately Modulates Cancer Progression. Cancer Res. 2019; 79(18):4557-4566. PMC: 6744958. DOI: 10.1158/0008-5472.CAN-18-3962. View

14.

Kim J, Piao H, Kim B, Yao F, Han Z, Wang Y . Long noncoding RNA MALAT1 suppresses breast cancer metastasis. Nat Genet. 2018; 50(12):1705-1715. PMC: 6265076. DOI: 10.1038/s41588-018-0252-3. View

15.

Kopp F, Mendell J . Functional Classification and Experimental Dissection of Long Noncoding RNAs. Cell. 2018; 172(3):393-407. PMC: 5978744. DOI: 10.1016/j.cell.2018.01.011. View

16.

Larkin J, Chiarion-Sileni V, Gonzalez R, Grob J, Rutkowski P, Lao C . Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. N Engl J Med. 2019; 381(16):1535-1546. DOI: 10.1056/NEJMoa1910836. View

17.

Leonardi G, Falzone L, Salemi R, Zanghi A, Spandidos D, McCubrey J . Cutaneous melanoma: From pathogenesis to therapy (Review). Int J Oncol. 2018; 52(4):1071-1080. PMC: 5843392. DOI: 10.3892/ijo.2018.4287. View

18.

Li Y, Shan Z, Liu C, Yang D, Wu J, Men C . MicroRNA-294 Promotes Cellular Proliferation and Motility through the PI3K/AKT and JAK/STAT Pathways by Upregulation of NRAS in Bladder Cancer. Biochemistry (Mosc). 2017; 82(4):474-482. DOI: 10.1134/S0006297917040095. View

19.

Li X, Jin F, Li Y . A novel autophagy-related lncRNA prognostic risk model for breast cancer. J Cell Mol Med. 2020; 25(1):4-14. PMC: 7810925. DOI: 10.1111/jcmm.15980. View

20.

Liao C, Hu N, Sun X, Zhou Q, Tian M, Cao Y . Identification and validation of tumor microenvironment-related lncRNA prognostic signature for uveal melanoma. Int J Ophthalmol. 2021; 14(8):1151-1159. PMC: 8342279. DOI: 10.18240/ijo.2021.08.03. View